Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 07:30PM GMT
Release Date Price: $189.6 (+1.77%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Hello, and once again welcome to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we jump into the next session, let me just go through the requisite disclosures.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. I'm getting very good at that, reading the disclosure there.

Questions & Answers

David Neil Lebowitz;John M. Maraganore
Morgan Stanley, Research Division - VP

So I'm very happy to have with me in the next session from Alnylam, CEO, John Maraganore. As always, I'm very happy to have you here. Let's start with the long-term vision. What is the long-term vision for Alnylam? And how has it evolved over the years?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot